Patrick Radden Keefe on How the Marketing of OxyContin Helped Create the Opioid Epidemic

The Political Scene | The New Yorker

The New Yorker

President, Barack, News, Politics, Wnyc, Obama, Lizza, Washington, Wickenden

4.3 • 3.9K Ratings

🗓️ 30 October 2017

⏱️ 23 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

When OxyContin came on the market, in 1995, physicians were understandably wary of the addictive potential of a powerful new opioid. As Patrick Radden Keefe reports, the manufacturer, Purdue Pharma, aggressively marketed OxyContin to physicians, claiming that the drug’s delayed-release mechanism could limit the risk of addiction. Instead, OxyContin led to many new addictions, and many addicted patients eventually sought street drugs like heroin. Steven May started at Purdue Pharma as a sales rep in 1999, and years later went on to allege fraud against Purdue as a participant in a whistle-blower lawsuit (which was dismissed on procedural grounds). May tells Keefe that he was trained to market the drug as one “to start with and to stay with,” despite seeing early on its addictive potential.

Purdue Pharma is a privately held company controlled by members of the Sackler family, who have a net worth of thirteen billion dollars. The Sacklers have donated handsomely to cancer research, medical schools, art museums, and universities. But Keefe tells David Remnick that the Sacklers have donated “nothing for the opioid crisis. Nothing for addiction treatment. If there is any sense in that family that they bear any moral culpability for where we are today, they’re not acting on it.”

Learn about your ad choices: dovetail.prx.org/ad-choices

Transcript

Click on a timestamp to play from that location

0:00.0	Hi there, I'm Lale Arikoglu, and this podcast is brought to you by Wilderness, a conservation-driven
0:06.4	hospitality company that offers intimate world life encounters in extraordinary remote landscapes.
0:12.5	Last year, I embarked on two separate solo adventures with Wilderness, one to Botswana and the other
0:18.2	to Namibia, where the expert guides delivered a truly once-in-a-lifetime
0:23.6	experience. I promise you, whatever you watch and see before you go won't prepare you for the thrill
0:29.4	of a wilderness adventure. eBay, it's a place to fall in love with new pre-loved vintage and rare
0:36.6	fashion over and over again.
0:39.0	Your favorite designers, expertly authenticated.
0:42.5	Yeah, eBay. Things people love.
0:48.5	I'm Dorothy Wickendon. On today's Politics and More podcast, the New Yorker's Patrick Radden-Keefe talks to Stephen May,
0:56.8	a former salesman at Purdue Pharma, the company that manufactures OxyContin.
1:02.3	May explains how the aggressive marketing of the drug may have contributed to the opioid crisis.
1:09.6	When the drug OxyContin first came into the market in 1995, it was advertised as a breakthrough.
1:17.2	An opioid that would manage pain better and would actually reduce the potential for addiction.
1:23.3	But just two decades later, OxyContin is a name that's become almost infamous in American life as the opioid crisis reaches truly awful proportions.
1:33.3	The New Yorker's Patrick Radin-Keefe has been reporting on Purdue Pharma, the company that developed OxyContin and the Sackler family, which controls it.
1:42.1	One of the people Patrick spoke with was a man named Stephen May,
1:45.4	an insider who saw exactly how the company's marketing worked. May is a former sales rep for
1:50.7	Purdue, and he started there in 1999 as sales of Oxycontin were booming. Tell me, for starters,
1:58.2	how did you first come to get into pharmaceutical sales?
2:03.6	Well, actually, I actually had a neighbor that lived near me back in the late 90s, who was a pharmaceutical sales representative.
2:14.6	And I saw that he had a really successful career. And, you know, it was
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The New Yorker, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The New Yorker and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.